A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin

Palmer, Daniel H.; Stocken, Deborah; Buckels, J. A. C.; Hewitt, Helen; Markham, C.; Mirza, D.; Johnson, Philip J.; Hassan, Adla B; Bramhall, Simon R.

doi:10.1200/jco.2004.22.90140.4215

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two phase II trials suggest a positive impact of neoadjuvant chemotherapy. Combination chemotherapy with either gemcitabine/cisplatin or gemcitabine-/docetaxel-induced resection rates of 69% and 79%, respectively [9,10]. Since the superiority of neoadjuvant treatment has not been demonstrated in phase III studies, this treatment option is not recommended outside of clinical trials.…”

Section: Neoadjuvant Therapymentioning

confidence: 98%

Future perspectives in the treatment of pancreatic cancer

Heinemann

2008

memo

View full text Add to dashboard Cite

Progress in the treatment of advanced pancreatic cancer occurs at small incremental steps. Adjuvant chemotherapy has become a widely accepted standard of care in resectable pancreatic cancer and has a positive impact on survival. Treatment of locally advanced non-metastatic pancreatic cancer is more controversial. First results indicate that secondary chemo-radiotherapy (CRT) may be benefi cial in patients who respond to initial chemotherapy. In metastatic pancreatic cancer chemotherapy with gemcitabine is a widely accepted standard of care. Among a multitude of combination therapies, only the combination of gemcitabine plus erlotinib has been registered for the treatment of pancreatic cancer. Further progress is expected from the exploration of new targeted agents, their integration into new concepts of chemotherapy, and the defi nition of predictive factors which may help to choose adequate treatment strategies for selected patient subgroups.

show abstract

Section: Neoadjuvant Therapymentioning

confidence: 98%

Future perspectives in the treatment of pancreatic cancer

Heinemann

2008

memo

View full text Add to dashboard Cite

show abstract

“…The combination treatment improved the resection rate from 38% to 69% and 1-year survival from 46% to 61% [8]. This result needs, however, to be viewed critically.…”

Section: The Concept Of Neoadjuvant Treatmentmentioning

confidence: 98%

Current adjuvant and neoadjuvant treatment concepts in pancreatic cancer

Heinemann

2009

Eur Surg

View full text Add to dashboard Cite

Zusammenfassung. Grundlagen: Die primäre chirurgische Resektion ist der etablierte Standard in der Behandlung des resektablen Pankreaskarzinoms. Während die neoadjuvante Therapie des resektablen Pankreaskarzinoms nicht durch randomisierte Studien unterstützt wird und daher außerhalb von Studien auch nicht empfohlen wird, so müssen multimodale Behandlungsstrategien für Tumoren mit Borderline-Resektabilität entwickelt werden.Methodik: Ü bersicht zur adjuvanten und neoadjuvanten Behandlung des resektablen Pankreaskarzinoms.Ergebnisse und Schlussfolgerungen: Der signifikante Nutzen der adjuvanten Chemotherapie hinsichtlich des krankheitsfreien Ü berlebens und des Gesamtüberlebens wurde in mehreren großen randomisierten Studien belegt. In den zuletzt publizierten Studien wurde mit Hilfe der adjuvanten Chemotherapie ein Gesamtüberleben von 20 bis 23 Monaten und ein 1-Jahresüberleben von etwa 20 % erreicht. Sowohl Gemcitabin als auch 5-Fluorouracil=Folinsäure zeigen eine vergleichbare Effektivität, die Medikamente unterscheiden sich aber hinsichtlich ihres Nebenwirkungsspektrums. Die klinische Bedeutung einer zusätzlich zur systemischen Chemotherapie verabreichten modernen Radiochemotherapie muss noch geklärt werden.Schlüsselwörter: Resektables Pankreaskarzinom, adjuvante Chemotherapie, Radiochemotherapie, Gemcitabin, 5-Fluorouracil=Folinsäure.Summary. Background: Primary surgical resection remains the treatment of choice in resectable pancreatic cancer. While neoadjuvant therapy of resectable pancreatic cancer is not supported by evidence from randomized trials, multimodal treatment needs to be developed specifically for borderline-resectable tumors.Methods: Review on current adjuvant and neoadjuvant treatment concepts in pancreatic cancer.Results and conclusions: The significant benefit from adjuvant chemotherapy with regard to disease-free and overall survival was demonstrated by several randomized studies. The most recent clinical trials using adjuvant chemotherapy consistently indicate that median survival times of 20-23 months and 1-year survival of 20% can be achieved. Both, gemcitabine and 5-fluorouracil=folinic acid have shown comparable efficacy, but differ in their side effects. The clinical importance of modern chemoradiotherapy in addition to systemic chemotherapy remains to be clarified.

show abstract

Perioperative management of pancreatic cancer

Boeck¹

2008

Annals of Oncology

View full text Add to dashboard Cite

A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin

Cited by 3 publications

References 0 publications

Future perspectives in the treatment of pancreatic cancer

Future perspectives in the treatment of pancreatic cancer

Current adjuvant and neoadjuvant treatment concepts in pancreatic cancer

Perioperative management of pancreatic cancer

Contact Info

Product

Resources

About